Thursday, November 06, 2014 9:46:26 AM
MNTA has stated that they have:
- 2 molecules partnered with Baxter and that they have a suite of
- 6 additional biosimilars in early development based on CHO, SB2 and NS0 cell lines.
So Baxter could chose additional biosimilars from these 6 programs and they could potentially partner some out
Additionally they have:
- NEcuparanib,
- Copaxone and
- 3 additional programs in Ivg, SIF3 and anti-FcRn
This is a full plate for such a small company, very bright future if Copaxone would given them revenue for the next 3 years to push forward.
What do you think about Necuparanib vs Puma Biotechnology which has only one cancer molecule and its worth 7 billion dollars in market cap?
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM